Understanding the causes of ventricular tachycardia
Ventricular Tachycardia Substrate Mechanisms Revealed by Local Repolarization and Conduction Parameters
This study is trying to find out what causes ventricular tachycardia by looking at heart tissue during treatment to help improve the success of the procedure for patients.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 10 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Emory University Academic / other |
| Locations | 3 sites (Atlanta, Georgia and 2 other locations) |
| Trial ID | NCT05478213 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the mechanisms behind ventricular tachycardia (VT) by examining the electrical properties of heart tissue. Researchers will utilize a Monophasic Action Potential (MAP) catheter during standard VT ablation procedures to identify critical areas of the myocardium that may lead to arrhythmias. The goal is to improve the success rates of VT ablation, which currently have a high recurrence rate despite advancements in technology. By better understanding the cellular action potentials, the study hopes to enhance patient outcomes during VT treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are patients diagnosed with ischemic cardiomyopathy who have a single or dual chamber implantable cardioverter-defibrillator.
Not a fit: Patients with non-ischemic cardiomyopathy or those who have contraindications to catheter ablation may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved outcomes for patients undergoing ventricular tachycardia ablation.
How similar studies have performed: Previous studies have shown modest improvements in VT ablation success rates using various mapping techniques, but this approach utilizing MAP signals is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of ischemic cardiomyopathy * Single or dual chamber implantable cardioverter-defibrillator (ICD) Exclusion Criteria: * Non-Ischemic cardiomyopathy * Contraindication to catheter ablation * Severe peripheral arterial disease or medical condition that prohibit arterial access * Ventricular tachycardia (VT) or sudden cardiac arrest (SCA) within 30 days of acute coronary syndrome or within 90 days of coronary revascularization
Where this trial is running
Atlanta, Georgia and 2 other locations
- Emory University Hospital Midtown — Atlanta, Georgia, United States (Recruiting)
- Emory Clinic — Atlanta, Georgia, United States (Recruiting)
- Emory University Hospital — Atlanta, Georgia, United States (Recruiting)
Study contacts
- Principal investigator: Neal Bhatia, MD — Emory University
- Study coordinator: Neal Bhatia, MD
- Email: neal.kumar.bhatia@emory.edu
- Phone: 404-686-7878
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.